Diabetes Weight Loss Drug — Which Is Which? Untangling Ozempic, Mounjaro, Wegovy, Zepbound, Foundayo (2026)

Searching for “diabetes weight loss drug” lands you in a confusing brand-name landscape: Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo, Saxenda, Rybelsus, Trulicity. Here is the short answer. Ozempic and Mounjaro are FDA-approved for type 2 diabetes only. Wegovy, Zepbound, Foundayo, and Saxenda are FDA-approved for chronic weight management. Some share active ingredients with different brand names — Ozempic + Wegovy are both semaglutide; Mounjaro + Zepbound are both tirzepatide. Insurance covers each brand only for its FDA-approved indication. Below: the full untangling.

The brand-to-indication mapping

For the deep dive on Trulicity (dulaglutide) specifically — why its off-label weight-loss effect is meaningfully smaller than Wegovy or Zepbound, what AWARD-11 actually showed at the 4.5 mg max dose, and how the BLA-biologic regulatory pathway differs from the NDA/generic pathway most other GLP-1s follow — see our Trulicity (dulaglutide) for weight loss evidence guide .

Why does the same molecule have two brand names?

Because the FDA approves drugs by indication, not by molecule. When Novo Nordisk wanted to market semaglutide for chronic weight management, they couldn't just expand the Ozempic label — they had to run a separate phase 3 program (the STEP trials) and submit a separate New Drug Application targeting the obesity indication. The FDA approved that NDA under the brand name Wegovy. Same molecule, new label, new indication, new brand. Same story for Lilly and tirzepatide: Mounjaro for diabetes (SURPASS trials), Zepbound for obesity (SURMOUNT trials). For the question-by-question disambiguation hub answering all 21 patient-language same-as / class-membership / brand-vs-generic questions in one FAQPage-schema reference, see our GLP-1 disambiguation FAQ hub .

This matters because insurance coverage attaches to the brand-indication pair, not to the molecule. A Cigna or Aetna plan that covers Mounjaro for type 2 diabetes will not cover Mounjaro for off-label weight loss in a non-diabetic patient. The same plan may cover Zepbound for the same patient under the obesity indication. The molecule is identical; the coverage is not.

Magnitude: why the brand matters when the molecule is the same

The molecule is identical between Ozempic and Wegovy (semaglutide) and between Mounjaro and Zepbound (tirzepatide) — but the FDA-approved maximum dose, the trial population, and the studied endpoint are not. Ozempic tops out at 2 mg/week for type 2 diabetes; Wegovy goes to 2.4 mg/week for chronic weight management. Mounjaro and Zepbound both top out at 15 mg/week. The diabetes brands were trialed in patients with T2D and a lower baseline BMI on shorter trials; the weight-management brands were trialed in patients with obesity, higher baseline BMI, and longer follow-up. The headline weight-loss numbers below come from the pivotal trial each brand cites in its FDA label.

Three things to read off this chart. (1) Same molecule, different brand ≈ different magnitude. Ozempic and Wegovy are both semaglutide, but Wegovy at 2.4 mg in a 68-week obesity trial produced roughly 2.4× the percent body-weight reduction that Ozempic at 1 mg produced in a 40-week diabetes trial. Same drug, very different number. (2) The diabetes-vs-obesity gap is real even at the same molecule and same dose. Tirzepatide at 15 mg produced −12% TBWL in the SURPASS-2 T2D population vs −20.9% in the SURMOUNT-1 obesity population. Longer trial, higher baseline BMI, and a weight-loss-specific endpoint all push the obesity-brand number higher. (3) Brand choice is not just a label question. When a patient on Mounjaro for T2D asks “will I lose as much weight as someone on Zepbound,” the honest answer is “probably less, because the trial population, trial duration, and baseline weight all favor the weight-management brand's reported number.” The molecule does the work; the brand frames the expectation.

The off-label question

Patients sometimes ask whether they can use Ozempic or Mounjaro for weight loss without a type 2 diabetes diagnosis. Answer: legal but problematic.

• Off-label prescribing is legal. Prescribers can write any FDA-approved drug for any clinical indication they judge appropriate. Many prescribers write Ozempic or Mounjaro for non-diabetic patients seeking weight loss.
• Insurance plans will deny it. Both Cigna CNF 360 and Aetna 5468-C explicitly gate Mounjaro behind a documented type 2 diabetes diagnosis (with metformin step-therapy). Cigna's Conditions Not Covered clause (CNF 360 p.5 verbatim): “The GLP-1 agonists … in this policy are not FDA-approved for weight loss in a patient who is overweight (BMI ≥ 27 kg/m²) or obese (BMI ≥ 30 kg/m²) without type 2 diabetes.”
• Cash-pay options exist but are uneven. Wegovy through NovoCare self-pay is $299/mo (the weight-management semaglutide brand). Zepbound through LillyDirect Self Pay Journey Program is $299–$449/mo (the weight-management tirzepatide brand). Mounjaro has no DTC self-pay path — only the Mounjaro Savings Card for commercially insured patients with diabetes coverage. So the practical cash-pay path for non-diabetic weight loss is Wegovy or Zepbound, not off-label Ozempic or Mounjaro. For the Mounjaro-anchored alternatives walkthrough (same tirzepatide via Zepbound, different T2D GLP-1, or pivoting to an FDA-approved weight-management drug), see Mounjaro alternatives — T2D-specifically .
• The molecule is identical. If you have access to either the diabetes brand or the weight-management brand, your clinical experience is the same. Same dosing, same titration, same side-effect profile, same boxed warning.

Quick decision: which one are you asking your prescriber about?

• Have type 2 diabetes: Mounjaro (Lilly) or Ozempic (Novo). Insurance covers both with prior auth + metformin step therapy. See Aetna PA guide for verbatim policy language.
• Have obesity / overweight + comorbidity, NOT diabetes: Wegovy (semaglutide), Zepbound (tirzepatide), Foundayo (oral orforglipron), or Saxenda (older liraglutide). Insurance covers with PA + 3- or 6-month documented behavioral/dietary modification trial (per Cigna IP0206 / Aetna 4774-C respectively).
• Have BOTH diabetes AND obesity: talk to your prescriber about whether Mounjaro (diabetes brand; weight loss as a side benefit) or Zepbound (obesity brand; glycemic improvement as a side benefit) is the cleaner insurance path for you. Some patients can use only one path; some can use either.
• Want the largest possible weight loss: tirzepatide (Zepbound for the weight-management indication) per SURMOUNT-5 (NEJM 2025), which showed tirzepatide produces greater mean weight loss than semaglutide in head-to-head.

Related untangling articles

• Rybelsus alternatives: when oral semaglutide isn't working — switching to Foundayo, Wegovy, or compounded
• Wegovy vs Ozempic vs Zepbound vs Mounjaro: Side-by-Side Comparison & Brand Cheat Sheet
• Mounjaro vs Zepbound: Same Drug, Different Brand Names — Complete Side-by-Side Comparison
• Wegovy vs Mounjaro: Different Molecules, Different Indications — How to Choose
• GLP-1 Pills 2026: Rybelsus (T2D-only), Foundayo (weight-management) & Wegovy Oral — Side-by-Side Comparison of Every Oral GLP-1
• GLP-1 complete guide

Further reading

• GLP-1 diabetes medication interactions cheat sheet
• STEP-2 trial deep-dive (semaglutide in adults with type 2 diabetes)